VEEV

226.41

-0.61%↓

A

114.62

-0.73%↓

HQY

87.94

-0.25%↓

PDCO

31.27

+0.06%↑

PHR.US

25.9

+0.39%↑

VEEV

226.41

-0.61%↓

A

114.62

-0.73%↓

HQY

87.94

-0.25%↓

PDCO

31.27

+0.06%↑

PHR.US

25.9

+0.39%↑

VEEV

226.41

-0.61%↓

A

114.62

-0.73%↓

HQY

87.94

-0.25%↓

PDCO

31.27

+0.06%↑

PHR.US

25.9

+0.39%↑

VEEV

226.41

-0.61%↓

A

114.62

-0.73%↓

HQY

87.94

-0.25%↓

PDCO

31.27

+0.06%↑

PHR.US

25.9

+0.39%↑

VEEV

226.41

-0.61%↓

A

114.62

-0.73%↓

HQY

87.94

-0.25%↓

PDCO

31.27

+0.06%↑

PHR.US

25.9

+0.39%↑

Medtronic PLC

Отворен

СекторЗдравеопазване

88.14 -1.07

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

87.4

Максимум

88.97

Ключови измерители

By Trading Economics

Приходи

32M

1.3B

Продажби

-111M

8.3B

P/E

Средно за сектора

27.396

63.778

EPS

1.39

Дивидентна доходност

3.12

Марж на печалбата

15.798

Служители

95,000

EBITDA

-40M

2.4B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+8.94% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.12%

2.39%

Следващи печалби

22.05.2025 г.

Следваща дата на дивидент

11.04.2025 г.

Следваща дата на екс-дивидент

27.06.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-5.4B

115B

Предишно отваряне

89.21

Предишно затваряне

88.14

Настроения в новините

By Acuity

23%

77%

57 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Medtronic PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.02.2025 г., 12:24 ч. UTC

Печалби

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19.11.2024 г., 12:27 ч. UTC

Печалби

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27.02.2025 г., 10:30 ч. UTC

Топ новини

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18.02.2025 г., 11:47 ч. UTC

Печалби

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18.02.2025 г., 11:46 ч. UTC

Печалби

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q Adj EPS $1.39 >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q Net $1.29B >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q Diabetes Rev $694M >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q EPS $1.01 >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18.02.2025 г., 11:45 ч. UTC

Печалби

Medtronic 3Q Sales $8.29B >MDT

18.02.2025 г., 10:01 ч. UTC

Печалби
Горещи акции

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21.01.2025 г., 19:15 ч. UTC

Топ новини

Medtronic Hires CFO From Renault -- Update

21.01.2025 г., 12:17 ч. UTC

Топ новини

Medtronic Hires CFO From Renault

19.11.2024 г., 12:12 ч. UTC

Печалби

Medtronic Narrows FY Guidance as 2Q Tops Views

19.11.2024 г., 11:46 ч. UTC

Печалби

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19.11.2024 г., 11:46 ч. UTC

Печалби

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic 2Q Adj EPS $1.26 >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic 2Q Diabetes Rev $686M >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic 2Q Net $1.27B >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19.11.2024 г., 11:45 ч. UTC

Печалби

Medtronic 2Q Sales $8.4B >MDT

Сравнение с други в отрасъла

Ценова промяна

Medtronic PLC Прогноза

Ценова цел

By TipRanks

8.94% нагоре

12-месечна прогноза

Среден 96.4 USD  8.94%

Висок 109 USD

Нисък 85 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Medtronic PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

19 ratings

9

Купи

9

Задържане

1

Продай

Техническа оценка

By Trading Central

88.02 / 90.29Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

57 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.